EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives $26.63 Consensus PT from Analysts

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) have been assigned a consensus rating of “Buy” from the ten analysts that are covering the firm, MarketBeat Ratings reports. Ten investment analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $26.63.

A number of research firms recently issued reports on EYPT. Citigroup began coverage on shares of EyePoint Pharmaceuticals in a research report on Tuesday, January 7th. They set a “buy” rating and a $33.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research report on Thursday, December 5th. Scotiabank started coverage on EyePoint Pharmaceuticals in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $18.00 target price for the company. Chardan Capital increased their price target on EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Finally, StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st.

Institutional Investors Weigh In On EyePoint Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Essex Investment Management Co. LLC grew its stake in shares of EyePoint Pharmaceuticals by 234.2% in the 3rd quarter. Essex Investment Management Co. LLC now owns 142,144 shares of the company’s stock worth $1,136,000 after acquiring an additional 99,606 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in EyePoint Pharmaceuticals by 5.9% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 142,763 shares of the company’s stock worth $1,141,000 after purchasing an additional 7,967 shares in the last quarter. Geode Capital Management LLC increased its stake in EyePoint Pharmaceuticals by 16.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,199,056 shares of the company’s stock valued at $9,583,000 after buying an additional 166,699 shares during the last quarter. Barclays PLC increased its stake in EyePoint Pharmaceuticals by 410.4% in the 3rd quarter. Barclays PLC now owns 245,045 shares of the company’s stock valued at $1,959,000 after buying an additional 197,033 shares during the last quarter. Finally, Patient Square Capital LP bought a new position in shares of EyePoint Pharmaceuticals during the 3rd quarter worth approximately $10,882,000. 99.41% of the stock is owned by hedge funds and other institutional investors.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT stock opened at $7.27 on Friday. The company has a market cap of $496.18 million, a P/E ratio of -3.64 and a beta of 1.49. EyePoint Pharmaceuticals has a fifty-two week low of $6.90 and a fifty-two week high of $30.99. The stock has a 50 day simple moving average of $8.49 and a two-hundred day simple moving average of $8.96.

About EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.